Unknown PHASE2 INTERVENTIONAL 1-arm NCT01066429

DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma

Treatment With Infusional Dose-adjusted Etoposide/Vincristine/Doxorubicin/Bolus Cyclophosphamide/Dexamethasone and Rituximab (DA-EDOCH14-R) in Patients With Poor-prognosis Diffuse Large B-cell Lymphoma

Sponsor: Hospital Universitario Principe de Asturias

Conditions Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions Dexamethasone and dose-dense immunochemoterapy

Updated 6 times since 2017 Last updated: Feb 11, 2010 Started: Dec 31, 2009 Primary completion: Dec 31, 2010 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diffuse Large B-Cell Lymphoma (DLBCL), this trial is ongoing. The trial is conducted by Hospital Universitario Principe de Asturias and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Universitario Principe de Asturias

Data source: Hospital Universitario Principe de Asturias

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Alcalá de Henares, Spain